Cited 0 time in
Correction: Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Shin, Jinho | - |
| dc.contributor.author | Cha, Dong Hoon | - |
| dc.contributor.author | Bae, Woo-Hyung | - |
| dc.contributor.author | Jung, In Hyun | - |
| dc.contributor.author | Hong, Seung-Pyo | - |
| dc.contributor.author | Kim, Sang-Hyun | - |
| dc.contributor.author | Do, Jun-Young | - |
| dc.contributor.author | Hwang, Won Min | - |
| dc.contributor.author | Koh, Young Youp | - |
| dc.contributor.author | Mancia, Giuseppe | - |
| dc.contributor.author | Manolis, Athanasios J. | - |
| dc.contributor.author | Lee, Minyoung | - |
| dc.date.accessioned | 2025-11-27T06:30:41Z | - |
| dc.date.available | 2025-11-27T06:30:41Z | - |
| dc.date.issued | 2025-07 | - |
| dc.identifier.issn | 2635-6325 | - |
| dc.identifier.issn | 2056-5909 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/209390 | - |
| dc.description.abstract | This corrects the article “Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study” in volume 31, e8. Correction to: Clinical Hypertension (2025) 31:e8 https://doi.org/10.5646/ch.2025.31.e8 Following publication of the original article [1], the authors reported an error in Figure 2. The labels in the figure were incorrect and have been corrected as follows: Original labels: < 70 beats/min, 70–79 beats/min, and ≥ 80 beats/min Corrected labels: < 1 beats/min, 1–9 beats/min, and ≥ 10 beats/min The original article [1] has been corrected. © 2025 The Korean Society of Hypertension. | - |
| dc.format.extent | 3 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Korean Society of Hypertension | BioMed Central | - |
| dc.title | Correction: Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study | - |
| dc.title.alternative | Correction: Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.5646/ch.2025.31.e24 | - |
| dc.identifier.scopusid | 2-s2.0-105010413209 | - |
| dc.identifier.wosid | 001523258400001 | - |
| dc.identifier.bibliographicCitation | Clinical Hypertension, v.31, no.1, pp 1 - 3 | - |
| dc.citation.title | Clinical Hypertension | - |
| dc.citation.volume | 31 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 3 | - |
| dc.type.docType | Correction | - |
| dc.identifier.kciid | ART003222267 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | esci | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
| dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
| dc.subject.keywordPlus | clinical trial | - |
| dc.subject.keywordPlus | diagnosis | - |
| dc.subject.keywordPlus | erratum | - |
| dc.subject.keywordPlus | human | - |
| dc.subject.keywordPlus | major clinical study | - |
| dc.subject.keywordPlus | randomized controlled trial | - |
| dc.identifier.url | https://clinicalhypertension.org/DOIx.php?id=10.5646/ch.2025.31.e24 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
